实用医学杂志2026，Vol.42Issue(8)：1379-1387,9.DOI:10.3969/j.issn.1006-5725.2026.08.011
聚乙二醇干扰素α治疗慢性乙型肝炎疗效的预测指标相关研究进展
Research progress on predictive indicators for the efficacy of pegylated interferon alpha in the treatment of chronic hepatitis B
摘要
Abstract
Pegylated interferon alpha(Peg-IFN-α)demonstrates dual antiviral and immunomodulatory properties,which allow a subset of chronic hepatitis B(CHB)patients to attain high hepatitis B surface antigen(HBsAg)clearance rates within a limited treatment period.This,in turn,presents the potential for clinical cure and a reduced risk of hepatocellular carcinoma.Nevertheless,its clinical application is restricted by high costs,significant adverse effects,and considerable inter-individual variability in therapeutic response.This highlights the need for accurate patient stratification.This review systematically assesses host-related factors(including age,gender,baseline alanine aminotransferase levels,interferon-related gene polymorphisms,and hepatic fibrosis status)and virological parameters(such as HBV genotype,viral mutations,viral load,and antigen/novel viral marker levels)that impact Peg-IFN-α treatment outcomes.By clarifying their predictive value and mechanistic roles,analyzing current therapeutic challenges,and suggesting individualized treatment strategies,this work aims to promote the optimization of clinical management protocols for CHB.关键词
慢性乙型肝炎/聚乙二醇干扰素α/优势人群/乙肝病毒表面抗原/预测因子Key words
chronic hepatitis B/pegylated interferon alpha/advantageous individuals/hepatitis B surface antigen/predictors分类
医药卫生引用本文复制引用
陈丝丝,李玉婷,阎岩..聚乙二醇干扰素α治疗慢性乙型肝炎疗效的预测指标相关研究进展[J].实用医学杂志,2026,42(8):1379-1387,9.基金项目
国家自然科学基金项目(编号:81701550) （编号:81701550）
无锡市卫健委中青年拔尖人才资助计划(编号:BJ2023092) （编号:BJ2023092）
无锡市"太湖人才计划"顶尖医学专家团队项目(编号:锡卫人[2025]2号) （编号:锡卫人[2025]2号）
